| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Aligos Therapeutics, Inc. have bought $0 and sold $0 worth of Aligos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aligos Therapeutics, Inc. have bought $6M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,933,601 shares for transaction amount of $6M was made by Nuechterlein Carole () on 2023‑10‑25.
| 2023-10-25 | Nuechterlein Carole | 7.93M 22.4566% | $0.76 | $6M | +4.10% | |||
| 2020-10-20 | Vivo Capital VIII, LLC | 10 percent owner | 550,000 1.9863% | $15.00 | $8.25M | +61.44% | ||
| 2020-10-20 | Novo Holdings A/S | 10 percent owner | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
| 2020-10-20 | Woiwode Thomas | director | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
| 2020-10-20 | Versant Venture Capital VI, L.P. | director | 400,000 1.4446% | $15.00 | $6M | +61.44% |
| Nuechterlein Carole | 11025941 178.1882% | $87.55M | 1 | 0 | +4.1% | |
| Vivo Capital VIII, LLC | 10 percent owner | 3116658 50.3677% | $24.75M | 1 | 0 | +61.44% |
| Novo Holdings A/S | 10 percent owner | 2614563 42.2535% | $20.76M | 1 | 0 | +61.44% |
| Woiwode Thomas | director | 862444 13.9378% | $6.85M | 1 | 0 | +61.44% |
| Versant Venture Capital VI, L.P. | director | 862444 13.9378% | $6.85M | 1 | 0 | +61.44% |
$5,626,766 | 114 | -34.35% | $46.39M | |
$155,630,608 | 79 | -24.53% | $50.95M | |
$4,898,715 | 46 | 40.75% | $56.27M | |
$226,127 | 22 | -27.62% | $49.42M | |
$17,594,514 | 16 | -20.37% | $56.96M | |
$91,209,456 | 15 | -7.00% | $43.66M | |
$277,862 | 15 | 59.79% | $53.62M | |
$39,336,371 | 14 | -17.87% | $43.43M | |
$19,300,035 | 11 | 45.88% | $54.18M | |
$20,042,003 | 10 | -19.50% | $53.13M | |
$31,610,161 | 9 | -73.83% | $49.5M | |
$45,000,000 | 6 | -31.22% | $57.48M | |
Aligos Therapeutics, Inc. (ALGS) | $26,254,149 | 5 | 49.97% | $49.13M |
$5,306,958 | 5 | 11.70% | $48.35M | |
$49,127 | 3 | -42.90% | $46.43M | |
$67,369,250 | 3 | -22.09% | $48.91M | |
$40,985 | 3 | -50.46% | $44.34M | |
$30,190 | 1 | -42.39% | $45.16M | |
$4,030 | 1 | 9.14% | $46.87M |
| Increased Positions | 22 | +61.11% | 750,143 | +28.29% |
| Decreased Positions | 12 | -33.33% | 590,230 | -22.26% |
| New Positions | 13 | New | 568,995 | New |
| Sold Out Positions | 5 | Sold Out | 383,728 | Sold Out |
| Total Postitions | 46 | +27.78% | 3M | +6.03% |
| Woodline Partners Lp | $4,275.00 | 9.36% | 468,199 | -50,101 | -9.67% | 2025-09-30 |
| Deep Track Capital, Lp | $4,055.00 | 8.88% | 444,110 | 0 | 0% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $3,762.00 | 8.24% | 412,000 | 0 | 0% | 2025-09-30 |
| Sio Capital Management, Llc | $3,067.00 | 6.72% | 335,937 | 0 | 0% | 2025-09-30 |
| Readystate Asset Management Lp | $1,854.00 | 4.06% | 203,113 | +66,331 | +48.49% | 2025-09-30 |
| Vanguard Group Inc | $1,568.00 | 3.43% | 171,689 | +31,913 | +22.83% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $1,278.00 | 2.8% | 140,000 | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $758.00 | 1.66% | 83,055 | 0 | 0% | 2025-09-30 |
| Hhlr Advisors, Ltd. | $696.00 | 1.53% | 76,247 | 0 | 0% | 2025-09-30 |
| Lpl Financial Llc | $503.00 | 1.1% | 55,120 | +25,020 | +83.12% | 2025-09-30 |